Radiation affects both tumor and normal tissues, limiting the total delivered radiation dose. Therefore, novel ways to exploit molecular targets and improve the therapeutic ratio are continually being investigated. Autophagy plays an important role in cancer cell death decisions, particularly in solid tumors. This is counterbalanced by its function in cellular energy preservation. Recent studies have attempted to exploit autophagy in order to improve therapeutic ratio. However, direct inhibition of autophagy has been demonstrated to promote cancer cell death or survival dependent on cell type and condition. The mammalian target of rapamycin (mTOR) also regulates autophagy, as well as cell survival and proliferation pathways. Therefore, inhibition at this level of signaling would represent an excellent therapeutic target as it would limit cell growth, decrease cell proliferation, and boost autophagocytosis. Current investigations of mTOR inhibitors in combination with radiation appear to potentiate radiation's ability to induce autophagy. Further studies are necessary to fully elucidate which tumors have the most robust induction of autophagy in response to mTOR inhibition and radiation.
Introduction
Radiotherapy is integral to the treatment of many cancer types. Though it has been very effective, benefits have been limited by cytotoxicity of normal tissues. Multiple strategies have been employed to improve the therapeutic ratio for irradiation. These have included technological advances in dose delivery (e.g., intensity modulated radiotherapy and new forms of brachytherapy), alteration in dose fractionation strategies, and radiosensitization or enhancement with various chemotherapeutic and biologic agents. Radiosensitization has traditionally been performed with agents known to induce apoptosis. It is well established that radiation-induction of cell death varies with tumor cell type (1, 2). Radiationinduced apoptosis is prominent in thymocytes, lymphocytes, and cells from hematopoeitic and germinal lineages. However, apoptosis represents a very small proportion of radiation-induced cell death in solid tumors. In solid tumors, autophagy, or type II programmed cell death, plays a much more important role.
Programmed Cell Death
Programmed cell death was first described morphologically in the early 1970s (3, 4) . Those early studies were re-visited by Clarke (5) , and he was able to classify programmed cell death into Type I and II based on those morphological characteristics. and subsequent formation of apoptotic bodies (i.e., fragmented cellular debris) (6, 7). Apoptosis is known to be primarily mediated by caspase (cysteine aspartate proteases) proteins, and the apoptotic bodies undergo lysosomal digestion by neighboring phagocytes in a process known as heterophagocytosis. The process has also been characterized by DNA laddering noted on Southern blot analysis (8).
Type II programmed cell death, or autophagy, is a reversible process characterized by the appearance of double (or multiple) membrane-enclosed cytoplasmic vesicles containing organelles and/or cytoplasmic polypeptides. These vesicles undergo degradation by fusion with intracellular lysosomes (autophagosomes), in a process known as autophagocytosis.
There is no DNA fragmentation or formation of apoptotic bodies. Morphological studies suggest that some cells do have both morphological phenotypes, which suggests that cells have the ability to have concomitant activation of multiple death mechanisms (8).
Autophagy is complex in that it has dual roles. It functions as a protective mechanism for cell survival, as well as a cell death mechanism for eliminating damaged cells. In normal cells, autophagy serves a housekeeping role, which involves degradation of intracellular components. This can occur in response to stressful stimuli (e.g., starvation or hypoxia) or in the presence of faulty or redundant polypeptides or organelles. Type II programmed cell death is most often associated with cancer and cancer therapy.
Autophagy and Cancer
Mutation of autophagy-specific genes (e.g., beclin-1 and ATG5) has been associated with tumorigenesis, suggesting a possible tumor suppressor role. For example, beclin-1, an essential autophagy gene, is deleted in a large number of cancer cell lines (9, 10). Heterozygosity of the beclin-1 locus also results in a high rate of spontaneous tumorigenesis (11, 12) . Furthermore, overexpression of beclin-1 (and ATG5) prevents tumor formation in human xenograft models of breast cancer (13). This represents a wealth of independent evidence suggesting a role in tumor suppression.
Autophagy may also have dual roles in cancer. It promotes survival of cancer cells during nutrient starvation, as well as survival of cancer cells that have outstripped their vascular supply (e.g., hypoxia, metabolic stress). It has been proposed to remove dysfunctional mitochondria and endoplasmic reticulum, possibly decreasing the total amount of oxidative stress thereby allowing for tumor survival. Autophagy promotes death by limiting or regulating cell growth, or suppressing tumorigenesis by promoting cell death.
However, when stress conditions are excessive, autophagy becomes a suicide pathway whereby cells self-digest. This is especially apparent when other death mechanisms, such as apoptosis, are deficient or unavailable. For example, previous studies showed that endoplasmic reticulum (ER) stress can induce autophagic cell death (14, 15) . Similarly, many anticancer therapies, including radiation, has also been shown to enhance autophagy when apoptosis is inhibited (16, 17) .
Irradiation has been demonstrated to induce autophagic cell death in various cancer cell types. In glioblastoma cells, there was no evidence of radiation-induced apoptosis, but autophagy was induced in both radiosensitive and radioresistant cell lines (18). All cell lines underwent transient suppression of cell proliferation in a dose-responsive manner, though the radioresistant cell lines required higher doses of radiotherapy to exert that effect. The study was limited in that it did not quantitate autophagy, nor could it be determined if autophagy represented a death or survival signal. Daido et al. also studied the effect of radiation on malignant glioma cells. They demonstrated that low-dose ionizing radiation induces cell death in cells deficient in DNA-PK, but not in those with intact DNA-PK (18). Other tumor types have also demonstrated radiation-induced autophagy, including breast cancer (17, (19) (20) (21) , prostate cancer (22), and lung cancer (17).
The scope of this review is the interaction of irradiation and autophagy, but it is noteworthy that other DNA damaging agents have also been implicated in autophagy-induced cell death. These include chemotherapeutic agents such as camptothecin in breast cancer cells (23) and temozolomide in glioma cells (16).
Interplay of Apoptosis and Autophagy
There is a complex relationship between apoptosis and autophagy. They are regulated by similar factors. For example, bcl-2 (an anti-apoptotic mitochondrial protein) is known to directly bind beclin-1 thereby inhibiting autophagy. In addition, beclin-1 mutants that are unable to bind bcl-2 exhibit excessive autophagocytosis and cell death (24). Both pathways have also been demonstrated to be inhibited by similar signaling cascades (e.g., PI3K/Akt/mTOR, NF-κB).
Based on these observations, studies have been conducted that demonstrated that blocking one mode of death can result in enhancement of the other mode of death. For example, in experiments where apoptosis is blocked using siRNA to Bak/Bax, radiation-induced cell death through autophagy was increased. This result was found in muiltiple tumor cell lines, including prostate, lung, and breast cancer cells (17). This concept was further tested using Bak/Bax -/-(double knock-out) mouse embryonic fibroblasts (MEF), which showed a decrease in Akt/mTOR signaling but a significant increase in pro-autophagic proteins in response to radiation (17). The Bak/Bax -/-MEFs were also found to be more sensitive to radiation induced autophagy compared with wild type MEFs (17) 
mTOR Pathway
The mammalian target of rapamycin (e.g., mTOR, RAFT1, RAPT1, FRAP) is a 289 kDa serine-threonine kinase downstream in the PI3K-Akt pathway. This kinase has a wellestablished role in phosphorylation and inactivation of the translation suppressor eukaryotic initiation factor 4E-binding protein 1 (4E-BP1, PHAS1). It also phosphorylates and activates the ribosomal p70S6 kinase. The mTOR protein is involved in two functionally distinct regulatory complexes, mTORC1 and mTORC2 (28).
The mTORC1 complex consists of mTOR, G protein β-subunit-like protein (mLST8/G βL), and raptor (regulator-associated protein of mTOR). This complex is rapamycin-sensitive. It has been shown to inhibit autophagy (29), through poorly understood mechanisms. The mTORC1 complex also functions in regulation of protein synthesis, cell cycle progression, and cellular proliferation. The mTORC2 complex consists of mTOR, mLST8/G βL, rictor, and mSin1 (mitogen-activaedprotein-kinase-associated protein 1). It has been described as rapamycin insensitive, though there is recent evidence that it may be sensitized with prolonged treatment through se-questration of mTOR molecules (30). This complex primarily functions in regulation of actin organization, but recent studies have demonstrated that it also directly phosphorylates Akt on the Ser473 residue (31, 32) . The significance of this relationship is not yet fully understood, but suggests that it may be activate Akt upstream of the mTORC1 complex. A recent publication by Zeng et al. utilized in vitro and in vivo acute myeloid leukemia cells to provide the first evidence that mTOR inhibitors (particularly CCI-779 and RAD-001) can inhibit Akt signaling (33). These inhibitors unexpectedly inhibited both mTORC1 and mTORC2, but blocked Akt activation through inhibition of the mTORC2 complex.
The PI3K/Akt/mTOR pathway is overactive in multiple cancer cell types, in some cases as a result of PTEN (phosphatase and tensin homologue) mutation resulting in loss of tumor suppression of mTOR and increased cell growth, cell survival, and anti-autophagic signals. Thus, mTOR has emerged as an important target for radiosensitization in that inhibition at this level of the survival cascade would limit growth and survival, while promoting autophagy. Multiple mTOR inhibitors, based on rapamycin, have been developed, and RAD-001 (everolimus) has been used extensively to study mTOR's inhibitory effects on normal tissues and tumor cells. Interestingly, increased activation of the Akt/ mTOR pathway is seen in transformed cells (Aoki et al., 2001) . This suggests that cancer cells may be better targets for mTOR inhibition. Interestingly, increased activation of the Akt/mTOR pathway is seen in transformed cells (34). This suggests that cancer cells may be better targets for mTOR inhibition. Consistent with this hypothesis, Albert et al. reported that mTOR inhibitors are indeed more effective in killing tumor cells than normal cells (21).
Iwamaru et al. demonstrated that rapamycin treatment of malignant glioma cells resulted in cell death. Administration of siRNA to beclin-1 abrograted the cell death, strongly suggesting that death was autophagy-dependent (35).
In Cao et al., experiments were carried out with PTEN +/+ and PTEN -/-prostate cell lines treated with RAD-001 and radiation (22). RAD-001 induced little autophagy alone, however when combined with radiation there was a significant increase in autophagy in both PTEN +/+ and PTEN -/prostate cell lines. There was a greater amount of cell death and autophagy in the PTEN null line. Their results suggested that hyperactive PI3K/Akt/mTOR results in some tumor advantage, and this can be overcome by inhibition of mTOR signaling through mTORC1 or mTORC2.
Conclusion
Targeting of autophagy may be exploitable, but has proven to be difficult. It is dependent on cell type, apoptotic machin- ery functionality, as well as the type of therapeutic modality. We have discussed in vitro evidence demonstrating increased death in the presence of stress stimuli and low autophagy (autophagy inhibitor), as well as evidence of increased tumor survival in conditions of high autophagy and stress stimuli conditions. In addition, we have discussed recent studies of apoptotic inhibition, which in some models has resulted in radiosensitization. Though it is early to determine what tumor types may be sensitive to inhibition of autophagy or apoptosis, there are clues in recently performed studies. In solid tumors dependent mostly on radiation-induced cell death through autophagy, like malignant glioma cells, inhibition of apoptosis does seem to sensitize tumor cells to increased autophagy. DNA damage of cells that are primarily dependent on apoptosis-mediated death pathways, like lymphocytes, has been demonstrated to increased cell death in response to autophagy inhibition. Investigations into this fine interplay between autophagy and apoptosis are being rapidly undertaken, and potentially these further investigations are necessary to develop better predictive models (36). For now, targeting autophagy directly may not be as valuable as the less selective inhibition of mTOR and its associated complexes.
Inhibition of mTORC1 and/or mTORC2 results in decreased cell survival and proliferation signals, while inhibition of mTORC1 also promotes autophagy. The strategy of targeting mTOR signaling has been proven to be an effective means of radiosensitizing target tumors, as it is likely to exploit changes in cell survival, proliferation, and autophagy. With better understanding of the autophagic and apoptotic cell paths and their interactions, we anticipate that the combination of targeted therapies to these paths in combination with radiation can be tailored for treatment of individual tumor types. The growing knowledge of cell death mechanisms provides the rationale for the development of new strategies based on the combination of DNA damaging agents with targeted biologic therapies.
